Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
58 hedge funds and large institutions have $9.31M invested in Oncternal Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 10 closing their positions.
2,700% more call options, than puts
Call options by funds: $28K | Put options by funds: $1K
6% more capital invested
Capital invested by funds: $8.79M → $9.31M (+$520K)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
5% less funds holding
Funds holding: 61 → 58 (-3)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$572K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$267K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$54.1K |
| 4 |
BC
BIT Capital
Berlin,
Germany
|
+$48.3K |
| 5 |
WCA
Waypoint Capital Advisors
Minneapolis,
Minnesota
|
+$38.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$735K |
| 2 |
Two Sigma Investments
New York
|
-$180K |
| 3 |
E
Ergoteles
New York
|
-$87.8K |
| 4 |
Two Sigma Advisers
New York
|
-$79.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48K |
ONCT Hedge Fund Activity: Q4 2022 in Review
58 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2022, worth a combined $9.31M — up 5.9% from $8.79M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ONCT and 9 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, adding an estimated $572K. The largest seller was Renaissance Technologies, cutting an estimated $735K.
- 58 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2022, down from 61 in Q3 2022.
- Funds reported $9.31M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2022, up 5.9% quarter-over-quarter.
- 9 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $572K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2022 was Renaissance Technologies, an estimated $735K sold.
Based on aggregated 13F filings for Q4 2022.